đź§  Big Pharma, AI & Mental Health

  • đź§  Big Pharma, AI & Mental Health

    Posted by IMA-HelenT on January 20, 2026 at 10:30 am EST

    IMA Senior Fellow Dr. Ryan Cole is joined by psychiatrist and former FDA medical officer Dr. Josef Witt-Doerring for an honest, wide-ranging discussion on the forces shaping mental health care today—from pharmaceutical influence on treatment guidelines to the rise of AI therapy bots, from screen time’s toll on developing brains to the ethical collapse represented by psychiatric euthanasia. They also address seasonal depression, the limits of the 15-minute visit, and why non-drug approaches remain underused despite strong evidence.

    This isn’t about quick fixes. It’s about stepping back, asking deeper questions, and reclaiming an approach to mental health that puts patients before billing codes.

    Watch Here: https://imahealth.org/rethinking-approach-to-mental-health/

    Jeff Gerber replied 3 weeks, 5 days ago 3 Members · 3 Replies
  • 3 Replies
  • Lenore Norrgard

    Member
    January 20, 2026 at 12:18 pm EST

    I have a 40yo client who has has suffered from OCD since she was a young child. She eschews pharma Rx medication. Anything you can say about what might help such a person would be appreciated. Thank you.

    • IMA-HelenT

      Organizer
      January 20, 2026 at 3:24 pm EST

      Thank you, have passed your question on to the show team.

  • Jeff Gerber

    Member
    January 20, 2026 at 11:13 pm EST

    It would be nice to hear thoughts on the use of Low Dose Ketamine therapy in mental health as recent research has shown that it has a wide range of psychiatric uses. Depression and ADHD are among them.

    Example: https://www.revivalinfusion.com/post/low-dose-ketamine-for-adhd-management-what-to-expect

    Leading Edge Clinic (Dr. Kory’s clinic) article: https://drpierrekory.com/blog/low-dose-ketamine-for-long-haul-covid-post-vaccine-syndrome-and-me-cfs/

    “In both published and unpublished case reports and series, the results they have achieved in their patients is nothing short of revolutionary. For the first time in their 20 and 40 year careers, they have seen dramatic recoveries in mood disorders, including:

    Major Depressive Disorder

    Treatment-resistant depression

    Bipolar disorder

    Anxiety disorders (GAD, PTSD, OCD, etc.)

    Borderline personality disorder, and many other psychiatric conditions.”

    I think low dose ketamine is another case of big pharma not being able to capture the market with a proprietary drug and this is why we don’t hear of it, yet it might be the most effective pharmacological treatment out there. We already know that SSRI’s don’t work and they hurt people.

Log in to reply.